Merger and acquisition news materialized in the days leading up to the J.P. Morgan Healthcare Conference, kicking off in San Francisco on 13 January, but deal watchers still were waiting for some deals to be finalized in the final hours before the annual meeting. GSK was the first out of the gate, late at night on the West Coast on 12 January, with its plan to buy IDRx for up to $1.15bn.
GSK Kicks Off M&A Push As Deal Speculation And Sunny Skies Set The Scene For J.P. Morgan
GSK will pay up to $1.15bn for IDRx, Lilly is said to be making a play for Scorpion, Biogen offered to buy Sage and Gilead announced a partnership with Leo Pharma ahead of the J.P. Morgan Healthcare Conference.
More from J.P. Morgan
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.
• By
Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.
• By
Despite a big market opportunity with an underserved patient population, investment in the therapeutic area lags and investor perception is a pressure point.
• By
Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.
More from R&D
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.